

| | | | |
|---|--|--|--|
| Form PTO-1449 (modified) | | Atty. Docket No.: DFCL:006US | Serial No.: 10/598,295 |
| List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary) | | | |
| U.S. Patent Documents <i>See Page 1-2</i> | | Foreign Patent Documents <i>See Page 2</i> | Other Art <i>See Page 3-19</i> |

U.S. Patent Documents

| Exam. Init. | Ref. Des. | Document Number | Date | Name | Class | Sub Class | Filing Date of App. |
|-------------|-----------|-----------------|----------|------------------------------------|-------|-----------|---------------------|
| | A1 | 10/553,028 | 10/11/05 | Belmares <i>et al.</i> | 514 | 018 | 10/11/05 |
| | A2 | 2002/0110841 | 08/15/02 | Kufe | 435 | 7.23 | 12/26/01 |
| | A3 | 2003/0148969 | 08/07/03 | Dobie <i>et al.</i> | 514 | 44 | 12/20/01 |
| | A4 | 2004/0018181 | 01/29/04 | Kufe <i>et al.</i> | 424 | 93.21 | 05/29/03 |
| | A5 | 2004/0166543 | 08/26/04 | Kufe | 435 | 7.23 | 12/11/03 |
| | A6 | 2004/0209832 | 10/21/04 | McSwiggen | 514 | 44 | 09/23/03 |
| | A7 | 2005/0042209 | 02/24/05 | Kufe <i>et al.</i> | 424 | 93.21 | 02/13/04 |
| | A8 | 2005/0053606 | 03/10/05 | Kufe <i>et al.</i> | 424 | 155.1 | 09/11/01 |
| | A9 | 5,506,343 | 04/09/96 | Kufe | 530 | 387.7 | 10/25/94 |
| | A10 | 5,530,101 | 06/25/96 | Queen <i>et al.</i> | 530 | 387.3 | 12/19/90 |
| | A11 | 5,612,895 | 03/18/97 | Balaji <i>et al.</i> | 702 | 19 | 04/21/95 |
| | A12 | 5,766,833 | 06/16/98 | Balance <i>et al.</i> | 435 | 69.7 | 11/17/93 |
| | A13 | 5,776,427 | 07/07/98 | Thorpe <i>et al.</i> | 424 | 1.49 | 06/01/95 |
| | A14 | 5,801,154 | 09/01/98 | Baracchini <i>et al.</i> | 514 | 44 | 04/08/97 |
| | A15 | 5,861,381 | 01/19/99 | Chambon <i>et al.</i> | 514 | 44 | 06/07/95 |
| | A16 | 5,998,148 | 12/07/99 | Bennett <i>et al.</i> | 435 | 6 | 04/08/99 |
| | A17 | 6,020,363 | 02/01/00 | Hirano <i>et al.</i> | 514 | 456 | 12/17/98 |
| | A18 | 6,054,438 | 04/25/00 | Taylor-Papadimitriou <i>et al.</i> | 514 | 44 | 06/01/95 |
| | A19 | 6,074,841 | 06/13/00 | Gearing <i>et al.</i> | 435 | 69.1 | 11/19/96 |
| | A20 | 6,222,020 | 04/24/01 | Taylor-Papadimitriou <i>et al.</i> | 530 | 395 | 06/01/95 |
| | A21 | 6,589,921 | 07/08/03 | Herrmann <i>et al.</i> | 514 | 456 | 02/27/01 |
| | A22 | 6,716,627 | 04/06/04 | Dobie | 435 | 375 | 12/20/01 |

25794698.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /SM/

| | | | |
|---|--|--|--|
| Form PTO-1449 (modified) | | Atty. Docket No.: DFCL:006US | Serial No.: 10/598,295 |
| List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary) | | | |
| U.S. Patent Documents <i>See Page 1-2</i> | | Foreign Patent Documents <i>See Page 2</i> | Other Art <i>See Page 3-19</i> |

U.S. Patent Documents

| Exam. Init. | Ref. Des. | Document Number | Date | Name | Class | Sub Class | Filing Date of App. |
|-------------|-----------|-----------------|----------|------------------------|-------|-----------|---------------------|
| | A23 | 60/308,307 | 07/27/01 | Kufe | | | 07/27/01 |
| | A24 | 60/502,111 | 09/11/03 | Jecminek <i>et al.</i> | | | 09/11/03 |

Foreign Patent Documents

| Exam. Init. | Ref. Des. | Document Number | Date | Country | Language |
|-------------|-----------|-----------------|----------|---------|----------|
| | B1 | EP 1103623 | 07/01/98 | Europe | English |
| | B2 | WO 00/25827 | 05/11/00 | WIPO | English |
| | B3 | WO 00/34468 | 06/15/00 | WIPO | English |
| | B4 | WO 00/77031 | 12/21/00 | WIPO | English |
| | B5 | WO 01/12217 | 02/22/01 | WIPO | English |
| | B6 | WO 01/18035 | 03/15/01 | WIPO | English |
| | B7 | WO 01/57068 | 08/09/01 | WIPO | English |
| | B8 | WO 02/058450 | 08/01/02 | WIPO | English |
| | B9 | WO 02/22685 | 03/21/02 | WIPO | English |
| | B10 | WO 02/31512 | 04/18/02 | WIPO | English |
| | B11 | WO 03/014303 | 02/20/03 | WIPO | English |
| | B12 | WO 03/088995 | 10/30/03 | WIPO | English |
| | B13 | WO 2004/044160 | 05/27/04 | WIPO | English |
| | B14 | WO 2004/092339 | 10/28/04 | WIPO | English |
| | B15 | WO 93/20841 | 10/28/93 | WIPO | English |
| | B16 | WO 96/03502 | 02/08/96 | WIPO | English |

25794698.1

| | |
|-----------|------------------|
| EXAMINER: | DATE CONSIDERED: |
|-----------|------------------|

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /SM/

| | | | |
|---|--|---|-----------------------------------|
| Form PTO-1449 (modified) | | Atty. Docket No.: | Serial No.: |
| | | DFCL:006US | 10/598,295 |
| List of Patents and Publications for Applicant's | | | |
| INFORMATION DISCLOSURE STATEMENT | | | |
| (Use several sheets if necessary) | | | |
| U.S. Patent Documents <i>See Page 1-2</i> | | Foreign Patent Documents <i>See Page 2</i> | Other Art <i>See Page 3-19</i> |

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

| Exam. Init. | Ref. Des. | Citation |
|-------------|-----------|--|
| | C1 | Adams and Cory, "The Bcl-2 Protein Family: Arbiters of Cell Survival," <i>Science</i> , 281:1322-1326, 1998. |
| | C2 | Agrawal and Kandimalla, "Antisense therapeutics: is it as simple as complementary base recognition?" <i>Molecular Medicine Today</i> , 6:72-81, 2000. |
| | C3 | Akagi <i>et al.</i> , "CA19-9 epitope a possible marker for MUC-1/Y protein," <i>Int. J. Oncol.</i> , 18:1085-1091, 2001. |
| | C4 | Ashkenazi and Dixit, "Apoptosis control by death and decoy receptors," <i>Curr. Opin. Cell Biol.</i> , 11:255-260, 1999. |
| | C5 | Ashkenazi and Dixit, "Death Receptors: Signaling and Modulation," <i>Science</i> , 281:1305-1308, 1998. |
| | C6 | Ashkenazi <i>et al.</i> , "Safety and antitumor activity of recombinant soluble Apo2 ligand," <i>J. Clin. Invest.</i> , 104:155-162, 1999. |
| | C7 | Backstrom <i>et al.</i> , "Recombinant MUC1 mucin with a breast cancer-like O-glycosylation produced in large amounts in Chinese-hamster ovary cells," <i>Biochemical Journal</i> , 376:677-686, 2003. |
| | C8 | Banerjee, "Omega amino acids in peptide design: incorporation into helices," <i>Biopolymers</i> , 39:769-77, 1996. |
| | C9 | Barry and Sharkey, "Observer reproducibility during computer-assisted planimetric measurements of nuclear features," <i>Hum. Pathol.</i> , 16:225-7, 1985. |
| | C10 | Barry <i>et al.</i> , "Activation of programmed cell death (apoptosis) by cisplatin, other anticancer drugs, toxins and hyperthermia," <i>Biochemical Pharmacology</i> , 40:2353-2362, 1990. |
| | C11 | Baruch <i>et al.</i> , "Preferential expression of novel MUC1 tumor antigen isoforms in human epithelial tumors and their tumor-potentiating function," <i>Int. J. Cancer</i> , 71:741-749, 1997. |
| | C12 | Baruch <i>et al.</i> , "The breast cancer-associated MUC1 gene generates both a receptor and its cognate binding protein," <i>Cancer Res.</i> , 59:1552-1561, 1999. |
| | C13 | Batra <i>et al.</i> , "Transfection of the human MUC1 mucin gene into a poorly differentiated human pancreatic tumor cell line, Panc1: integration, expression and ultrastructural changes," <i>J. Cell Science</i> , 100:841-849, 1991. |

25794698.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /SM/

| | | | |
|--|--|--|----------------------------|
| Form PTO-1449 (modified) | | Atty. Docket No.: | Serial No.: |
| | | DFCL:006US | 10/598,295 |
| List of Patents and Publications for Applicant's | | | |
| INFORMATION DISCLOSURE STATEMENT | | | |
| (Use several sheets if necessary) | | | |
| U.S. Patent Documents See Page 1-2 | | Foreign Patent Documents See Page 2 | Other Art See Page 3-19 |

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

| Exam. Init. | Ref. Des. | Citation |
|-------------|-----------|--|
| | C14 | Bellgrau <i>et al.</i> , "A role for CD95 ligand in preventing graft rejection," <i>Nature</i> , 377:630-632, 1995. |
| | C15 | Berger <i>et al.</i> , "Respiratory carcinoma cell lines: MUC genes and glycoconjugates," <i>American Journal of Respiratory Cell and Molecular Biology</i> , 20:500-510, 1999. |
| | C16 | Bergeron <i>et al.</i> , "MAUB is a new mucin antigen associated with bladder cancer," <i>J. Biol. Chem.</i> , 271:6933-6940, 1996. |
| | C17 | Beusen <i>et al.</i> , "Conformational mimicry: synthesis and solution conformation of a cyclic somatostatin hexapeptide containing a tetrazole cis amide bond surrogate," <i>Biopolymers</i> , 36:181-200, 1995. |
| | C18 | Bird <i>et al.</i> , "Single-chain antigen-binding proteins," <i>Science</i> , 242:423-6, 1988. |
| | C19 | Bitko <i>et al.</i> , "Inhibition of respiratory viruses by nasally administered siRNA," <i>Nature Med.</i> , 11:50-55, 2005. |
| | C20 | Bodmer <i>et al.</i> , "Cysteine 230 is essential for the structure and activity of the cytotoxic ligand TRAIL," <i>J. Biol. Chem.</i> , 275:20632-20637, 2000. |
| | C21 | Boldin <i>et al.</i> , "Involvement of MACH, a novel MORT1/FADD-interacting protease, in Fas/APO-1- and TNF receptor-induced cell death," <i>Cell</i> , 85:803-815, 1996 |
| | C22 | Brossart <i>et al.</i> , "Identification of HLA-A2-restricted T-cell epitopes derived from MUC1 tumor antigen for broadly applicable vaccine therapies," <i>Blood</i> , 93:4309-4317, 1999. |
| | C23 | Brunner <i>et al.</i> , "pangolin encodes a Lef-1 homologue that acts downstream of Armadillo to transduce the Wingless signal in <i>Drosophila</i> ," <i>Nature</i> , 385:829-33, 1997. |
| | C24 | Bumcrot <i>et al.</i> , "RNAi therapeutics: a potential new class of pharmaceutical drugs," <i>Nature Chemical Biology</i> , 2:711-719, 2006. |
| | C25 | Bunz, "Cell death and cancer therapy," <i>Curr. Opin. Pharmacol.</i> , 1:337-341, 2001. |
| | C26 | Burns and El-Deiry, "Identification of inhibitors of TRAIL-induced death (ITIDs) in the TRAIL-sensitive colon carcinoma cell line SW480 using a genetic approach," <i>J. Biol. Chem.</i> , 276:37879-37886, 2001. |
| | C27 | Busfield <i>et al.</i> , "Characterization of a neuregulin-related gene, <i>Don-1</i> , that is highly expressed in restricted regions of the cerebellum and hippocampus," <i>Mol. Cell. Biol.</i> , 17:4007-4014, 1997. |

25794698.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /SM/

| | | | |
|--|--|--|--|
| Form PTO-1449 (modified) | | Atty. Docket No.: DFCI:006US | Serial No.: 10/598,295 |
| List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT <small>(Use several sheets if necessary)</small> | | | |
| U.S. Patent Documents <i>See Page 1-2</i> | | Foreign Patent Documents <i>See Page 2</i> | Other Art <i>See Page 3-19</i> |

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

| Exam. Init. | Ref. Des. | Citation |
|-------------|-----------|---|
| | C28 | Chang <i>et al.</i> , "Ligands for ErbB-family receptors encoded by a neuregulin-like gene," <i>Nature</i> , 387:509-512, 1997. |
| | C29 | Chaudhary <i>et al.</i> , "A rapid method of cloning functional variable-region antibody genes in <i>Escherichia coli</i> as single-chain immunotoxins," <i>Proc. Natl. Acad. Sci. U.S.A.</i> , 87:1066-70, 1990. |
| | C30 | Ciborowski <i>et al.</i> , "Screening of anti-MUC1 antibodies for reactivity with native (ascites) and recombinant (baculovirus) MUC1 and for blocking MUC1 specific cytotoxic T-lymphocytes," <i>Tumor Biology</i> , 19:147-151, 1998. |
| | C31 | Console <i>et al.</i> , "Antennapedia and HIV transactivator of transcription (TAT) "protein transduction domains" promote endocytosis of high molecular weight cargo upon binding to cell surface glycosaminoglycans," <i>J. Biol. Chem.</i> , 278:35109-14, 2003. |
| | C32 | Creagan <i>et al.</i> , "Phase III clinical trial of the combination of cisplatin, dacarbazine, and carmustine with or without tamoxifen in patients with advanced malignant melanoma," <i>J. Clin. Oncol.</i> , 17:1884-1890, 1999. |
| | C33 | Daniel and Reynolds, "The catenin p120(ctn) interacts with Kaiso, a novel BTB/POZ domain zinc finger transcription factor," <i>Mol. Cell. Biol.</i> , 19:3614-23, 1999. |
| | C34 | Datta <i>et al.</i> , "Overexpression of Bcl-XL by cytotoxic drug exposure confers resistance to ionizing radiation-induced internucleosomal DNA fragmentation," <i>Cell Growth Differ.</i> , 6:363-370, 1995. |
| | C35 | Dawson <i>et al.</i> , "Synthesis of proteins by native chemical ligation," <i>Science</i> , 266:776-779, 1994. |
| | C36 | Deng <i>et al.</i> , "TRAIL-induced apoptosis requires Bax-dependent mitochondrial release of Smac/DIABLO," <i>Genes Dev.</i> , 16:33-45, 2002. |
| | C37 | Derossi <i>et al.</i> , "Cell internalization of the third helix of the Antennapedia homeodomain is receptor-independent," <i>J. Biol. Chem.</i> , 271:18188-93, 1996. |
| | C38 | Derossi <i>et al.</i> , "The third helix of the Antennapedia homeodomain translocates through biological membranes," <i>J. Biol. Chem.</i> , 269:10444-50, 1994. |
| | C39 | Deveraux and Reed, "IAP family proteins—suppressors of apoptosis," <i>Genes Dev.</i> , 13:239-52, 1999. |
| | C40 | Dillman, "Antibodies as cytotoxic therapy," <i>J. Clin. Oncology</i> , 12:1497-1515, 1994. |

25794698.1

| | |
|-----------|------------------|
| EXAMINER: | DATE CONSIDERED: |
|-----------|------------------|

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /SM/

| | | | |
|---|--|---|-----------------------------------|
| Form PTO-1449 (modified) | | Atty. Docket No.: DFCL:006US | Serial No.: 10/598,295 |
| List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary) | | | |
| U.S. Patent Documents <i>See Page 1-2</i> | | Foreign Patent Documents <i>See Page 2</i> | Other Art <i>See Page 3-19</i> |

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

| Exam. Init. | Ref. Des. | Citation |
|-------------|-----------|---|
| | C41 | Dorn <i>et al.</i> , "Down-regulation of the human tumor antigen mucin by gemcitabine on the pancreatic cancer cell line capan-2," <i>Anticancer Research</i> , 24:821-826, 2004. |
| | C42 | Doyle, "Crystal structures of a complexed and peptide-free membrane protein-binding domain: molecular basis of peptide recognition by PDZ," <i>Cell</i> , 85:1067-76, 1996. |
| | C43 | Drucker <i>et al.</i> , "Tamoxifen enhances apoptotic effect of cisplatin on primary endometrial cell cultures," <i>Anticancer Research</i> , 23:1549-1554, 2003. |
| | C44 | Du <i>et al.</i> , "Smac, a Mitochondrial Protein that Promotes Cytochrome c-Dependent Caspase Activation by Eliminating IAP Inhibition," <i>Cell</i> , 102:33-42, 2000. |
| | C45 | Dykxhoorn <i>et al.</i> , "The silent treatment: siRNAs as small molecule drugs," <i>Gene Therapy</i> , 13:541-552, 2006. |
| | C46 | Elbashir <i>et al.</i> , "Analysis of gene function in somatic mammalian cells using small interfering RNAs," <i>Methods</i> , 26:199-213, 2002. |
| | C47 | Elbashir <i>et al.</i> , "RNA interference is mediated by 21-and 22-nucleotide RNAs," <i>Genes and Development</i> , 15:188-200, 2001. |
| | C48 | Elliot and O'Hare, "Intercellular trafficking and protein delivery by a herpesvirus structural protein," <i>Cell</i> , 88:223-33, 1997. |
| | C49 | Elmquist <i>et al.</i> , "VE-cadherin-derived cell-penetrating peptide, pVEC, with carrier functions," <i>Exp. Cell Res.</i> , 269:237-44, 2001. |
| | C50 | Emoto <i>et al.</i> , "Proteolytic activation of protein kinase C delta by an ICE-like protease in apoptotic cells," <i>EMBO J.</i> , 14:6148-6156, 1995. |
| | C51 | Faivre <i>et al.</i> , "Supraadditive effect of 2',2'difluorodeoxycytidine (gemcitabine) in combination with oxaliplatin in human cancer cell lines," <i>Cancer Chemother. Pharmacol.</i> , 44:117-123, 1999. |
| | C52 | Feigl, "2,8-Dimethyl-4-(carboxymethyl)-6-(aminomethyl)phenoxythiin S-Dioxide: An Organic Substitute for the beta-Turn in Peptides," <i>J. Amer. Chem. Soc.</i> , 108:181-2, 1986. |
| | C53 | Finn <i>et al.</i> , "MUC-1 Epithelial Tumor Mucin-Based Immunity and Cancer Vaccines," <i>Immunol. Rev.</i> , 145:61-89, 1995. |
| | C54 | Frankel and Pabo, "Cellular uptake of the tat protein from human immunodeficiency virus," <i>Cell</i> , 55:1189-93, 1989. |

25794698.1

EXAMINER: _____ **DATE CONSIDERED:** _____

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)
ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /SM/

| | | | |
|--|--|---|-----------------------------------|
| Form PTO-1449 (modified) | | Atty. Docket No.: | Serial No.: |
| | | DFCL:006US | 10/598,295 |
| List of Patents and Publications for Applicant's | | | |
| INFORMATION DISCLOSURE STATEMENT | | | |
| (Use several sheets if necessary) | | | |
| U.S. Patent Documents <i>See Page 1-2</i> | | Foreign Patent Documents <i>See Page 2</i> | Other Art <i>See Page 3-19</i> |

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

| Exam. Init. | Ref. Des. | Citation |
|-------------|-----------|--|
| | C55 | French and Tschopp, "Inhibition of Death Receptor Signaling by FLICE-inhibitory Protein as a Mechanism for Immune Escape of Tumors," <i>J. Exp. Med.</i> , 190:891-893, 1999. |
| | C56 | Futaki <i>et al.</i> , "Arginine-rich peptides. An abundant source of membrane-permeable peptides having potential as carriers for intracellular protein delivery," <i>J. Biol. Chem.</i> , 276:5836-40, 2001. |
| | C57 | Geisbert <i>et al.</i> , "Postexposure Protection of Guinea Pigs against a Lethal Ebola Virus Challenge is Conferred by RNA Interference," <i>J. Infectious Diseases</i> , 193:1650-1657, 2006. |
| | C58 | Gendler <i>et al.</i> , "A highly immunogenic region of a human polymorphic epithelial mucin expressed by carcinomas is made up of tandem repeats," <i>J. Biol. Chem.</i> , 263:12820-12823, 1988. |
| | C59 | Gendler <i>et al.</i> , "Molecular cloning and expression of human tumor-associated polymorphic epithelial mucin," <i>J. Biol. Chem.</i> , 265:15286-15293, 1990. |
| | C60 | Gopalakrishnan <i>et al.</i> , "Application of Micro Arrayed Compound Screening (microARCS) to identify inhibitors of caspase-3," <i>J. Biomol. Screen</i> , 7:317-23, 2002. |
| | C61 | Green and Loewenstein, "Autonomous functional domains of chemically synthesized human immunodeficiency virus tat trans-activator protein," <i>Cell</i> , 55:1179-88, 1989. |
| | C62 | Griffith <i>et al.</i> , "CD95-Induced Apoptosis of Lymphocytes in an Immune Privileged Site Induces Immunological Tolerance," <i>Immunity</i> , 5:7-16, 1996. |
| | C63 | Gross <i>et al.</i> , "Caspase cleaved BID targets mitochondria and is required for cytochrome c release, while BCL-XL prevents this release but not tumor necrosis factor-R1/Fas death," <i>J. Biol. Chem.</i> , 274:1156-1163, 1999. |
| | C64 | Grzelinski <i>et al.</i> , "RNA interference-mediated gene silencing of pleiotrophin through polyethylenimine-complexed small interfering RNAs in vivo exerts antitumoral effects in glioblastoma xenografts," <i>Human Gene Therapy</i> , 17:751-766, 2006. |
| | C65 | Haim <i>et al.</i> , "Dexamethasone, cytarabine, ifosfamide, and cisplatin as salvage therapy in Non-Hodgkin lymphoma," <i>Am. J. Clin. Oncol.</i> , 22:47-50, 1999. |
| | C66 | Hammond <i>et al.</i> , "Post-transcriptional gene silencing by double-stranded RNA," <i>Nature Genetics</i> , 2:110-119, 2001. |
| | C67 | Hanson <i>et al.</i> , "MUC1 expression in primary breast cancer: the effect of tamoxifen treatment," <i>Breast Cancer Research and Treatment</i> , 67:215-222, 2001. |

25794698.1

EXAMINER: _____ DATE CONSIDERED: _____

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /SM/

| | | | |
|--|--|---|-----------------------------------|
| Form PTO-1449 (modified) | | Atty. Docket No.: | Serial No.: |
| | | DFCI:006US | 10/598,295 |
| List of Patents and Publications for Applicant's | | | |
| INFORMATION DISCLOSURE STATEMENT | | | |
| (Use several sheets if necessary) | | | |
| U.S. Patent Documents <i>See Page 1-2</i> | | Foreign Patent Documents <i>See Page 2</i> | Other Art <i>See Page 3-19</i> |

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

| Exam. Init. | Ref. Des. | Citation |
|-------------|-----------|--|
| | C68 | Harborth <i>et al.</i> , "Identification of essential genes in cultured mammalian cells using small interfering RNAs," <i>J. Cell Science</i> , 114:4557-4565, 2001. |
| | C69 | Harrison, "Peptide-surface association: the case of PDZ and PTB domains," <i>Cell</i> , 86:341-343, 1996. |
| | C70 | Hartman <i>et al.</i> , "MUC1 isoform specific monoclonal antibody 6E6/2 detects preferential expression of the novel MUC1/Y protein in breast and ovarian cancer," <i>Int. J. Cancer</i> , 82:256-267, 1999. |
| | C71 | Herr and Debatin, "Cellular stress response and apoptosis in cancer therapy," <i>Blood</i> , 98:2603-2614, 2001. |
| | C72 | Higashiyama <i>et al.</i> , "A novel brain-derived member of the epidermal growth factor family that interacts with ErbB3 and ErbB4," <i>J. Biochem.</i> , 122:675-680, 1997. |
| | C73 | Higgins, "Comparison of the solution conformations of a human immunodeficiency virus peptidomimetic and its retro-inverso isomer using 1H NMR spectroscopy," <i>J. Pept. Res.</i> , 50:421-35, 1997. |
| | C74 | Hird <i>et al.</i> , "Adjuvant therapy of ovarian cancer with radioactive monoclonal antibody," <i>Br. J. Cancer</i> , 68:403-406, 1993. |
| | C75 | Hruby <i>et al.</i> , "Design of peptides, proteins, and peptidomimetics in chi space," <i>Biopolymers</i> , 43:219-66, 1997. |
| | C76 | Hunt and Evans, "Till Death Us Do Part," <i>Science</i> , 293:1784-1785, 2001. |
| | C77 | Huston <i>et al.</i> , "Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in <i>Escherichia coli</i> ," <i>Proc. Natl. Acad. Sci. U.S.A.</i> , 85:5879-83, 1988. |
| | C78 | Hymowitz <i>et al.</i> , "Triggering cell death: the crystal structure of Apo2L/TRAIL in a complex with death receptor 5," <i>Mol. Cell.</i> , 4:563-571, 1999. |
| | C79 | Ikeda <i>et al.</i> , "Induction of redox imbalance and apoptosis in multiple myeloma cells by the novel triterpenoid 2-cyano-3, 12-dioxoolean-1, 9-dien-28-oic acid," <i>Molecular Cancer Therapeutics</i> , 3:39-45, 2004. |
| | C80 | Irmler <i>et al.</i> , "Inhibition of death receptor signals by cellular FLIP," <i>Nature</i> , 388:190-195, 1997. |

25794698.1

EXAMINER: _____ DATE CONSIDERED: _____

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /SM/

| | | | |
|--|--|---|-----------------------------------|
| Form PTO-1449 (modified) | | Atty. Docket No.: DFCI:006US | Serial No.: 10/598,295 |
| List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT <small>(Use several sheets if necessary)</small> | | | |
| U.S. Patent Documents <i>See Page 1-2</i> | | Foreign Patent Documents <i>See Page 2</i> | Other Art <i>See Page 3-19</i> |

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

| Exam. Init. | Ref. Des. | Citation |
|-------------|-----------|--|
| | C81 | Itzkowitz <i>et al.</i> , "Sialosyl-Tn. A novel mucin antigen associated with prognosis in colorectal cancer patients," <i>Cancer</i> , 66:1960-6, 1990. |
| | C82 | Jaattela <i>et al.</i> , "Bcl-x and Bcl-2 inhibit TNF and Fas-induced apoptosis and activation of phospholipase A2 in breast carcinoma cells," <i>Oncogene</i> , 10:2297-2305, 1995. |
| | C83 | Jawhari <i>et al.</i> , "Up-regulated cytoplasmic expression, with reduced membranous distribution, of the src substrate p120(ctn) in gastric carcinoma," <i>J. Pathol.</i> 189:180-5, 1999. |
| | C84 | Jen <i>et al.</i> , "Suppression of gene expression by targeted disruption of messenger RNA: available options and current strategies," <i>Stem Cells</i> , 18:307-319, 2000. |
| | C85 | Jin <i>et al.</i> , "CIAP1 and the serine protease HTRA2 are involved in a novel p53-dependent apoptosis pathway in mammals," <i>Genes Dev.</i> , 17:359-67, 2003. |
| | C86 | Kahn <i>et al.</i> , "Nonpeptide Mimetics of beta-Turns: A Facile Oxidative Intramolecular Cycloaddition of an Azodicarbonyl System," <i>J. Amer. Chem. Soc.</i> , 110:1638-9, 1988. |
| | C87 | Kahn, "The design and synthesis of mimetics of peptide beta-turns," <i>J. Molec. Recognition</i> , 1:75-9, 1988. |
| | C88 | Kalofonos <i>et al.</i> , "Kinetics, quantitative analysis and radioimmunolocalisation using indium-111-HMFG1 monoclonal antibody in patients with breast cancer," <i>Cr. J. Cancer</i> , 59:939-942, 1989. |
| | C89 | Kalofonos <i>et al.</i> , "Radioimmunoschintigraphy in patients with ovarian cancer," <i>Acta Oncologica</i> , 38:629-634, 1999. |
| | C90 | Karvinen <i>et al.</i> , "Homogeneous time-resolved fluorescence quenching assay (LANCE) for caspase-3," <i>J. Biomol. Screen.</i> , 7:223-31, 2002. |
| | C91 | Kataoka <i>et al.</i> , "FLIP prevents apoptosis induced by death receptors but not by perforin/granzyme B, chemotherapeutic drugs, and gamma irradiation," <i>J. Immunol.</i> , 161:3936-3942, 1998. |
| | C92 | Kayagaki <i>et al.</i> , "Metalloproteinase-mediated release of human Fas ligand," <i>J. Exp. Med.</i> , 182:1777-1783, 1995. |
| | C93 | Kemp and Stites, "A convenient preparation of derivatives of 3(s)-amino-109(r)-carboxy-1,6-diazacyclodeca-2,7-dione the dilactam of L-alph,gamma-diaminobutyric acid and d-glutamic acid: a beta-turn template," <i>Tet. Lett.</i> , 29:5057-60, 1988. |

25794698.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)
ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /SM/

| | | | |
|---|--|---|-----------------------------------|
| Form PTO-1449 (modified) | | Atty. Docket No.: | Serial No.: |
| | | DFC1:006US | 10/598,295 |
| List of Patents and Publications for Applicant's | | | |
| INFORMATION DISCLOSURE STATEMENT | | | |
| (Use several sheets if necessary) | | | |
| U.S. Patent Documents <i>See Page 1-2</i> | | Foreign Patent Documents <i>See Page 2</i> | Other Art <i>See Page 3-19</i> |

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

| Exam. Init. | Ref. Des. | Citation |
|-------------|-----------|--|
| | C94 | Kennerdell <i>et al.</i> , "Heritable gene silencing in <i>Drosophila</i> using double-stranded RNA," <i>Nature Biotechnology</i> , 17:896-898, 2000. |
| | C95 | Kharbanda <i>et al.</i> , "Nuclear signaling induced by ionizing radiation involves colocalization of the activated p56/p53lyn tyrosine kinase with p34cdc2," <i>Cancer Res.</i> , 56:3617-3621, 1996. |
| | C96 | Kim <i>et al.</i> , "Cholestryl oligoarginine delivering vascular endothelial growth factor siRNA effectively inhibits tumor growth in colon adenocarcinoma," <i>Molecular Therapy</i> , 14:343-350, 2006. |
| | C97 | Kischkel <i>et al.</i> , "Cytotoxicity-dependent APO-1 (Fas/CD95)-associated proteins form a death-inducing signalling complex (DISC) with the receptor," <i>EMBO J.</i> , 14:5579-5588, 1995. |
| | C98 | Kluck <i>et al.</i> , "The Release of Cytochrome c from Mitochondria: A Primary Site for BCL-2 Regulation of Apoptosis," <i>Science</i> , 275:1132-1136, 1997. |
| | C99 | Kondo <i>et al.</i> , "Decreased MUC1 expression induces E-Cadherin-mediated cell adhesion of breast cancer cell lines," <i>Cancer Research</i> , 58:2014-2019, 1998. |
| | C100 | Kroemer and Reed, "Mitochondrial control of cell death," <i>Nat. Med.</i> , 6:513-519, 2000. |
| | C101 | Kufe <i>et al.</i> , "Differential reactivity of a novel monoclonal antibody (DF3) with human malignant versus benign breast tumors," <i>Hybridoma</i> , 3:223-232, 1984. |
| | C102 | Kumar <i>et al.</i> , "Abrogation of the cell death response to oxidative stress by the c-Abl tyrosine kinase inhibitor ST1571," <i>Mol. Pharmacol.</i> , 63:276-282, 2003. |
| | C103 | Kuppuswamy <i>et al.</i> , "Multiple functional domains of Tat, the trans-activator of HIV-1, defined by mutational analysis," <i>Nucl. Acids Res.</i> , 17:3551-61, 1989. |
| | C104 | LaVallee <i>et al.</i> , "2-Methoxyestradiol up-regulates death receptor 5 and induces apoptosis through activation of the extrinsic pathway," <i>Cancer Research</i> , 63:468-475, 2003. |
| | C105 | LeBlanc <i>et al.</i> , "Tumor-cell resistance to death receptor-induced apoptosis through mutational inactivation of the proapoptotic Bcl-2 homolog Bax," <i>Nat. Med.</i> , 8:274-281, 2002. |
| | C106 | Lewis <i>et al.</i> , "Efficient delivery of siRNA for inhibition of gene expression in postnatal mice," <i>Nature Genetics</i> , 32:107-108, 2002. |
| | C107 | Li and Kufe, "The human DF3/MUC1 carcinoma-associated antigen signals nuclear localization of the catenin p120 ^{ctn} ," <i>Biochem. Biophys. Res. Commun.</i> , 281:440-443, 2001. |

25794698.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /SM/

| | | | |
|--|--|---|-----------------------------------|
| Form PTO-1449 (modified) | | Atty. Docket No.: DFC1:006US | Serial No.: 10/598,295 |
| List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT <small>(Use several sheets if necessary)</small> | | | |
| U.S. Patent Documents <i>See Page 1-2</i> | | Foreign Patent Documents <i>See Page 2</i> | Other Art <i>See Page 3-19</i> |

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

| Exam. Init. | Ref. Des. | Citation |
|-------------|-----------|--|
| | C108 | Li <i>et al.</i> , "Cleavage of BID by Caspase 8 Mediates the Mitochondrial Damage in the FAS Pathway of Apoptosis," <i>Cell</i> , 94:491-501, 1998. |
| | C109 | Li <i>et al.</i> , "Cytochrome c and dATP-Dependent Formation of Apaf-1/Caspase-9 Complex initiates and Apoptotic Protease Cascade," <i>Cell</i> , 91:479-489, 1997. |
| | C110 | Li <i>et al.</i> , "DF3/MUC1 signaling in multiple myeloma cells is regulated by interleukin-7," <i>Cancer Biol. Ther.</i> , 2:187-193, 2003. |
| | C111 | Li <i>et al.</i> , "Heregulin targets gamma-catenin to the nucleolus by a mechanism dependent on the DF3/MUC1 oncoprotein," <i>Mol. Cancer Res.</i> , 1:765-775, 2003. |
| | C112 | Li <i>et al.</i> , "Human DF3/MUC1 carcinoma-associated protein functions as an oncogene," <i>Oncogene</i> , 22:6107-6110, 2003. |
| | C113 | Li <i>et al.</i> , "Interaction of glycogen synthase kinase 3β with the DF3/MUC1 carcinoma-associated antigen and β-catenin," <i>Mol. Cell. Biol.</i> , 18:7216-7224, 1998. |
| | C114 | Li <i>et al.</i> , "The c-Src tyrosine kinase regulates signaling of the human DF3/MUC1 carcinoma-associated antigen with GSK3β and β-catenin," <i>J. Biol. Chem.</i> , 276:6061-6064, 2001. |
| | C115 | Li <i>et al.</i> , "The EGF receptor regulates interaction of the human DF3/MUC1 carcinoma antigen with c-SRC and β-catenin," <i>JBC Papers in Press</i> , manuscript C100359200, August 1, 2001. |
| | C116 | Li <i>et al.</i> , "The epidermal growth factor receptor regulates interaction of the human DF3/MUC1 carcinoma antigen with c-Src and beta-catenin," <i>J. Biol. Chem.</i> , 276:35236-42, 2001. |
| | C117 | Li <i>et al.</i> , "Using siRNA in prophylactic and therapeutic regimens against SARS coronavirus in Rhesus macaque," <i>Nature Med.</i> , 11:944-951, 2005. |
| | C118 | Ligtenberg <i>et al.</i> , "Cell associated episialin is a complex containing two proteins derived from a common precurso," <i>J. Biol. Chem.</i> , 267:6171-6177, 1992. |
| | C119 | Ligtenberg <i>et al.</i> , "Suppression of Cellular Aggregation by High Levels of Episialin," <i>Cancer Res.</i> , 52:2318-2324, 1992. |
| | C120 | Lin <i>et al.</i> , "Inhibition of nuclear translocation of transcription factor NF-κappa B by a synthetic peptide containing a cell membrane-permeable motif and nuclear localization sequence," <i>J. Biol. Chem.</i> , 270:14255-8, 1995. |
| | C121 | Liu <i>et al.</i> , "Identification of a functionally important sequence in the cytoplasmic tail of integrin beta 3 by using cell-permeable peptide analogs," <i>Proc. Natl Acad. Sci. U.S.A.</i> , 93:11819-24, 1996. |

25794698.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)
ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /SM/

| | | | |
|--|--|---|-----------------------------------|
| Form PTO-1449 (modified) | | Atty. Docket No.: DFCI:006US | Serial No.: 10/598,295 |
| List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT <small>(Use several sheets if necessary)</small> | | | |
| U.S. Patent Documents <i>See Page 1-2</i> | | Foreign Patent Documents <i>See Page 2</i> | Other Art <i>See Page 3-19</i> |

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

| Exam. Init. | Ref. Des. | Citation |
|-------------|-----------|--|
| | C122 | Liu <i>et al.</i> , "Induction of Apoptotic Program in Cell-Free Extracts: Requirement of dATP and Cytochrome c," <i>Cell</i> , 86:147-157, 1996. |
| | C123 | Luo <i>et al.</i> , "An efficient intrathecal delivery of small interfering RNA to the spinal cord and peripheral neurons," <i>Molecular Pain</i> , 1:29, 2005. |
| | C124 | Luo <i>et al.</i> , "Bid, A Bcl2 Interacting Protein, Mediates Cytochrome c Release from Mitochondria in Response to Activation of Cell Surface Death Receptors," <i>Cell</i> , 94:481-490, 1998. |
| | C125 | Makimura <i>et al.</i> , "Reducing hypothalamic AGRP by RNA interference increases metabolic rate and decreases body weight without influencing food intake," <i>BMC Neuroscience</i> , 3:18, 2002. |
| | C126 | Maraveyas <i>et al.</i> , "Pharmacokinetics and toxicity of an Yttrium-90-CITC-DTPA-HMFG1 radioimmunoconjugate for intraperitoneal radioimmunotherapy of ovarian cancer," <i>Cancer</i> , 73:1067-1075, 1994. |
| | C127 | Maraveyas <i>et al.</i> , "Pharmacokinetics, biodistribution, and dosimetry of specific and control radiolabeled monoclonal antibodies in patients with primary head and neck squamous cell carcinoma," <i>Cancer Research</i> , 55:1060-1069, 1995. |
| | C128 | Mariani <i>et al.</i> , "Regulation of cell surface APO-1/Fas (CD95) ligand expression by metalloproteases," <i>Eur. J. Immunol.</i> , 25:2303-2307, 1995. |
| | C129 | Marsters <i>et al.</i> , "A novel receptor for Apo2L/TRAIL contains a truncated death domain," <i>Curr. Biol.</i> , 7:1003-1006, 1997. |
| | C130 | Martinez <i>et al.</i> , "Single-stranded antisense siRNAs guide target RNA cleavage in RNAi," <i>Cell</i> , 110:563-574, 2002. |
| | C131 | Martins, "The serine protease Omi/HtrA2: a second mammalian protein with a Reaper-like function," <i>Cell Death Diff.</i> , 9:699-701, 2002. |
| | C132 | McGuckin <i>et al.</i> , "Prognostic significance of MUC1 epithelial mucin expression in breast cancer," <i>Human Pathology</i> , 26:432-439, 1995. |
| | C133 | Mi <i>et al.</i> , "Characterization of a class of cationic peptides able to facilitate efficient protein transduction in vitro and in vivo," <i>Mol. Ther.</i> , 2:339-47, 2000. |
| | C134 | Milik <i>et al.</i> , "Lung lymphocyte elimination by apoptosis in the murine response to intratracheal particulate antigen," <i>J. Clin. Invest.</i> , 99:1082-1091, 1997. |

25794698.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)
ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /SM/

| | | | |
|--|--|---|-----------------------------------|
| Form PTO-1449 (modified) | | Atty. Docket No.: DFCI:006US | Serial No.: 10/598,295 |
| List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT <small>(Use several sheets if necessary)</small> | | | |
| U.S. Patent Documents <i>See Page 1-2</i> | | Foreign Patent Documents <i>See Page 2</i> | Other Art <i>See Page 3-19</i> |

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

| Exam. Init. | Ref. Des. | Citation |
|-------------|-----------|--|
| | C135 | Minakuchi <i>et al.</i> , "Atelocollagen-mediated synthetic small interfering RNA delivery for effective gene silencing <i>in vitro</i> and <i>in vivo</i> ," <i>Nucleic Acids Research</i> , 32:e109, 2004. |
| | C136 | Molenaar <i>et al.</i> , "XTcf-3 transcription factor mediates beta-catenin-induced axis formation in <i>Xenopus</i> embryos," <i>Cell</i> , 86:391-9, 1996. |
| | C137 | Morris <i>et al.</i> , "A new peptide vector for efficient delivery of oligonucleotides into mammalian cells," <i>Nucleic Acid Res.</i> , 25:2730-6, 1997. |
| | C138 | Muzio <i>et al.</i> , "FLICE, A Novel FADD-Homologous ICE/CED-3-like Protease, Is Recruited to the CD95 (fas/APO-1) Death-Inducing Signaling Complex," <i>Cell</i> , 85:817-827, 1996. |
| | C139 | Nagai and Sato, "Synthesis of a bicyclic dipeptide with the shape of beta-turn central part," <i>Tet. Lett.</i> , 26:647-50, 1985. |
| | C140 | Nagata, "Apoptosis by Death Factor," <i>Cell</i> , 88:355-365, 1997. |
| | C141 | Nakamura <i>et al.</i> , "RNA interference targeting transforming growth factor-beta type II receptor suppresses ocular inflammation and fibrosis," <i>Molecular Vision</i> , 10:703-711, 2004. |
| | C142 | Nakashima <i>et al.</i> , "Inhibition of angiogenesis by a new isocoumarin, NM-3," <i>J. Antibiotics</i> , 52:426-428, 1999. |
| | C143 | Nicholson <i>et al.</i> , "Radioimmunotherapy after chemotherapy compared to chemotherapy alone in the treatment of advanced ovarian cancer: a matched analysis," <i>Oncology Reports</i> 5:223-226, 1998. |
| | C144 | Niethammer <i>et al.</i> , "CRIPt, a novel postsynaptic protein that binds to the third PDZ domain of PSD-95/SAP90," <i>Neuron</i> , 20:693-707, 1989. |
| | C145 | Niu <i>et al.</i> , "Inhibition of HPV 16 E6 oncogene expression by RNA interference <i>in vitro</i> and <i>in vivo</i> ," <i>Int. J. Gynecol. Cancer</i> , 16:743-751, 2006. |
| | C146 | Novak and Dedhar, "Signaling through beta-catenin and Lef/Tcf," <i>Cell Mol. Life Sci.</i> , 52:3-37, 1999. |
| | C147 | Obermair <i>et al.</i> , "Expression of MUC1 splice variants in benign and malignant ovarian tumours," <i>Int. J. Cancer</i> , 100:166-171, 2002. |
| | C148 | Oehlke <i>et al.</i> , "Cellular uptake of an alpha-helical amphipathic model peptide with the potential to deliver polar compounds into the cell interior non-endocytically," <i>Biochim. Biophys. Acta</i> , 1414: 127-39, 1998. |

25794698.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)
ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /SM/

| | | | |
|--|--|--|--|
| Form PTO-1449 (modified) | | Atty. Docket No.: DFCI:006US | Serial No.: 10/598,295 |
| List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT <small>(Use several sheets if necessary)</small> | | | |
| U.S. Patent Documents <i>See Page 1-2</i> | | Foreign Patent Documents <i>See Page 2</i> | Other Art <i>See Page 3-19</i> |

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

| Exam. Init. | Ref. Des. | Citation |
|-------------|-----------|---|
| | C149 | Okazaki <i>et al.</i> , "Downregulation of gastric mucin gene expression and its biosynthesis by dexamethasone in the human," <i>J. Clin. Gastroenterol.</i> , 27(suppl. 1):S91-S92, 1998. |
| | C150 | Opalinska <i>et al.</i> , "Nucleic-acid therapeutics: basic principles and recent applications," <i>Nature Reviews Drug Discovery</i> , 1:503-514, 2002. |
| | C151 | Padrón <i>et al.</i> , "Selective cell kill of the combination of gemcitabine and cisplatin in multilayered postconfluent tumor cell cultures," <i>Anti-Cancer Drugs</i> , 10:445-452, 1999. |
| | C152 | Palliser <i>et al.</i> , "An siRNA-based microbicide protects mice from lethal herpes simplex virus 2 infection," <i>Nature</i> , 439:89-94, 2006. |
| | C153 | Pan <i>et al.</i> , "An Antagonist Decoy Receptor and a Death Domain-Containing Receptor for TRAIL," <i>Science</i> , 277:815-818, 1997. |
| | C154 | Pan <i>et al.</i> , "The Receptor for the Cytotoxic Ligand TRAIL," <i>Science</i> , 276:111-113, 1997. |
| | C155 | Parrish <i>et al.</i> , "Functional anatomy of a dsRNA trigger: differential requirement for the two trigger strands in RNA interference," <i>Molecular Cell</i> , 8:1077-1087, 2000. |
| | C156 | Paszkiewicz-Gadek <i>et al.</i> , "Biosynthesis of MUC1 mucin in human endometrial adenocarcinoma is modulated by estradiol and tamoxifen," <i>Gynecol. Endocrinol.</i> , 17:37-44, 2003. |
| | C157 | Pavlovic <i>et al.</i> , "Targeting of non-small cell lung cancer using HMFG1- ^{99m} TC monoclonal antibodies," <i>Med Pregl.</i> , 46 Suppl 1:26-28, 1993 |
| | C158 | Perey <i>et al.</i> , "Tumor selective reactivity of a monoclonal antibody prepared against a recombinant peptide derived from the DF3 human breast carcinoma-associated antigen," <i>Cancer Research</i> , 52:2563-2568, 1992. |
| | C159 | Perez <i>et al.</i> , "Antennapedia homeobox as a signal for the cellular internalization and nuclear addressing of a small exogenous peptide," <i>J. Cell. Sci.</i> , 102:717-22, 1992. |
| | C160 | Pescarolo <i>et al.</i> , "A retro-inverso peptide homologous to helix 1 of c-Myc is a potent and specific inhibitor of proliferation in different cellular systems," <i>FASEB J.</i> , 15:31-3, 2001. |
| | C161 | Pitti <i>et al.</i> , "Induction of Apoptosis by Apo-2 Ligand, a New Member of the Tumor Necrosis Factor Cytokine Family," <i>J. Biol. Chem.</i> , 271:12687-12690, 1996. |
| | C162 | Pooga <i>et al.</i> , "Cell penetrating PNA constructs regulate galanin receptor levels and modify pain transmission <i>in vivo</i> ," <i>Nature Biotech.</i> , 16:857-61, 1998. |

25794698.1

EXAMINER:**DATE CONSIDERED:**

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)
ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /SM/

| | | | |
|--|--|---|-----------------------------------|
| Form PTO-1449 (modified) | | Atty. Docket No.: DFCI:006US | Serial No.: 10/598,295 |
| List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT <small>(Use several sheets if necessary)</small> | | | |
| U.S. Patent Documents <i>See Page 1-2</i> | | Foreign Patent Documents <i>See Page 2</i> | Other Art <i>See Page 3-19</i> |

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

| Exam. Init. | Ref. Des. | Citation |
|-------------|-----------|---|
| | C163 | Porowska <i>et al.</i> , "MUC1 expression in human breast cancer cells is altered by the factors affecting cell proliferation," <i>Neoplasma</i> , 49:104-109, 2002. |
| | C164 | Price <i>et al.</i> , "Summary report on the ISOBM TD-4 workshop: analysis of 56 monoclonal antibodies against the MUC1 mucin," San Diego, California, November 17-23, 1996, <i>Tumor Biol.</i> , 19:sup. 1:1-20, 1998. |
| | C165 | Reddish <i>et al.</i> , "Pre-immunotherapy serum CA27.29 (MUC-1) mucin level and CD69+ lymphocytes correlate with effects of Theratope sialyl-Tn-KLH cancer vaccine in active specific immunotherapy," <i>Cancer Immunol. Immunother.</i> , 42:303-9, 1996. |
| | C166 | Reich <i>et al.</i> , "Small interfering RNA (siRNA) targeting VEGF effectively inhibits ocular neovascularization in a mouse model," <i>Molecular Vision</i> , 9:210-216, 2003. |
| | C167 | Ren <i>et al.</i> , "Human MUC1 carcinoma-associated protein confers resistance to genotoxic anticancer agents," <i>Cancer Cell</i> , 5:163-175, 2004. |
| | C168 | Ren <i>et al.</i> , "Protein kinase C delta regulates function of the DF3/MUC1 carcinoma antigen in beta-catenin signaling," <i>J. Biol. Chem.</i> , 277:17616-17622, 2002. |
| | C169 | Reynolds <i>et al.</i> , "Identification of a new catenin: the tyrosine kinase substrate p120cas associates with E-cadherin complexes," <i>Mol. Cell. Biol.</i> , 14:8333-42, 1994. |
| | C170 | Reynolds <i>et al.</i> , "Transformation-specific tyrosine phosphorylation of a novel cellular protein in chicken cells expressing oncogenic variants of the avian cellular src gene," <i>Mol. Cell. Biol.</i> , 9:629-38, 1989. |
| | C171 | Rondinone, "Therapeutic potential of mai in metabolic diseases," <i>BioTechniques</i> , 40:S31-S36, 2006. |
| | C172 | Rousselle <i>et al.</i> , "New advances in the transport of doxorubicin through the blood-brain barrier by a peptide vector-mediated strategy," <i>Mol. Pharmacol.</i> , 57:679-86, 2000. |
| | C173 | Ruben <i>et al.</i> , "Structural and functional characterization of human immunodeficiency virus tat protein," <i>J. Virol.</i> , 63(1):1-8, 1989. |
| | C174 | Sato <i>et al.</i> , "FAP-1: A Protein Tyrosine Phosphatase That Associates with Fas," <i>Science</i> , 268:411-415, 1995. |
| | C175 | Scaffidi <i>et al.</i> , "Differential Modulation of Apoptosis Sensitivity in CD95 Type I and Type II Cells," <i>J. Biol. Chem.</i> , 274:22532-22538, 1999. |

25794698.1

EXAMINER: _____ **DATE CONSIDERED:** _____

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

 INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)
 ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /SM/

| | | | |
|--|--|--|--|
| Form PTO-1449 (modified) | | Atty. Docket No.: DFCI:006US | Serial No.: 10/598,295 |
| List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT <small>(Use several sheets if necessary)</small> | | | |
| U.S. Patent Documents <i>See Page 1-2</i> | | Foreign Patent Documents <i>See Page 2</i> | Other Art <i>See Page 3-19</i> |

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

| Exam. Init. | Ref. Des. | Citation |
|-------------|-----------|--|
| | C176 | Schiffelers <i>et al.</i> , "Cancer siRNA therapy by tumor selective delivery with ligand-targeted sterically stabilized nanoparticle," <i>Nucleic Acids Research</i> , 32:e149, 2004. |
| | C177 | Schneider <i>et al.</i> , "Mutagenesis and selection of PDZ domains that bind new protein targets," <i>Nat Biotech</i> , 17:170-5, 1998. |
| | C178 | Schultz <i>et al.</i> , "Specific interactions between the syntrophin PDZ domain and voltage-gated sodium channels," <i>Nat. Struct. Biol.</i> , 5:19-24, 1998. |
| | C179 | Schumacher <i>et al.</i> , "Immunoscintigraphy with positron emission tomography: Gallium-68 chelate imaging of breast cancer pretargeted with bispecific anti-MUC1/anti-Ga chelate antibodies," <i>Cancer Research</i> , 61:3712-3717, 2001. |
| | C180 | Shen <i>et al.</i> , "Suppression of ocular neovascularization with siRNA targeting VEGF receptor 1," <i>Gene Therapy</i> , 13:225-234, 2006. |
| | C181 | Shimazui <i>et al.</i> , "Prognostic value of cadherin-associated molecules (alpha-, beta-, and gamma-catenins and p120cas) in bladder tumors," <i>Cancer Res.</i> , 56:4154-8, 1996. |
| | C182 | Siddiqui <i>et al.</i> , "Isolation and sequencing of a cDNA coding for the human DF3 breast carcinoma-associated antigen," <i>Proc. Natl. Acad. Sci. USA</i> , 85:2320-2323, 1988. |
| | C183 | Smith and Waterman, "Comparison of Biosequences," <i>Adv. Appl. Math.</i> , 2:482-9, 1981. |
| | C184 | Smith, "Design, Synthesis, and Crystal Structure of a Pyrrolin-Based Peptidomimetic Possessing the Conformation of a beta-Strand: Potential Application to the Design of Novel Inhibitors of Proteolytic Enzymes," <i>J. Amer. Chem. Soc.</i> , 114:10672-4, 1992. |
| | C185 | Snyder <i>et al.</i> , "Treatment of Terminal Peritoneal Carcinomatosis by a Transducible p53-Activating peptide," <i>PLoS Biology</i> , 2:186-93, 2004. |
| | C186 | Songyang <i>et al.</i> , "Recognition of unique carboxyl-terminal motifs by distinct PDZ domains," <i>Science</i> , 275:73-7, 1997. |
| | C187 | Soomets <i>et al.</i> , "Deletion analogues of transportan," <i>Biochim. Biophys. Acta</i> , 1467:165-176, 2000. |
| | C188 | Soutschek <i>et al.</i> , "Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs," <i>Nature</i> , 432:173-178, 2004. |
| | C189 | Spatola, "A Peptide Backbone Modifications," In: <i>Chemistry and Biochemistry of Amino Acids, Peptides and Proteins</i> , 7:267-357, Marcell Dekker, NY, 1983. |

25794698.1

EXAMINER:**DATE CONSIDERED:**

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)
ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /SM/

| | | | |
|--|--|---|-----------------------------------|
| Form PTO-1449 (modified) | | Atty. Docket No.: DFCI:006US | Serial No.: 10/598,295 |
| List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT <small>(Use several sheets if necessary)</small> | | | |
| U.S. Patent Documents <i>See Page 1-2</i> | | Foreign Patent Documents <i>See Page 2</i> | Other Art <i>See Page 3-19</i> |

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

| Exam. Init. | Ref. Des. | Citation |
|-------------|-----------|--|
| | C190 | Srinivasan <i>et al.</i> , "Bcl-xL functions downstream of caspase-8 to inhibit Fas- and tumor necrosis factor receptor 1-induced apoptosis of MCF7 breast carcinoma cells," <i>J. Biol. Chem.</i> , 273:4523-4529, 1998. |
| | C191 | Srinivasula <i>et al.</i> , "Autoactivation of procaspase-9 by Apaf-1-mediated oligomerization," <i>Mol. Cell.</i> , 1:949-957, 1998. |
| | C192 | Stennicke <i>et al.</i> , "Pro-caspase-3 is a major physiologic target of caspase-8," <i>J. Biol. Chem.</i> , 273:27084-27090, 1998. |
| | C193 | Strous and Decker, "Mucin-Type Glycoproteins," <i>Crit. Rev. Biochem., Mol. Biol.</i> , 27:57-92, 1992. |
| | C194 | Subbarao <i>et al.</i> , "pH-dependent bilayer destabilization by an amphipathic peptide," <i>Biochemistry</i> , 26:2964-2972, 1987. |
| | C195 | Takei <i>et al.</i> , "A small interfering RNA targeting vascular endothelial growth factor as cancer therapeutics," <i>Cancer Research</i> , 64:3365-3370, 2004. |
| | C196 | Takeichi, "Cadherins: a molecular family important in selective cell-cell adhesion," <i>Annu. Rev. Biochem.</i> , 59:237-52, 1990. |
| | C197 | Taylor <i>et al.</i> , "Antisense oligonucleotides: a systematic high-throughput approach to target validation and gene function determination," <i>Drug Discovery Today</i> , 4:562-567, 1999. |
| | C198 | Thakker <i>et al.</i> , "siRNA-mediated knockdown of the serotonin transporter in the adult mouse brain," <i>Molecular Psychiatry</i> , 10:782-789, 2005. |
| | C199 | Timmer <i>et al.</i> , "Fas receptor-mediated apoptosis: a clinical application?" <i>J. Pathol.</i> , 196:125-134, 2002. |
| | C200 | Tondini <i>et al.</i> , "Evaluation of monoclonal antibody DF3 conjugated with ricin as a specific immunotoxin for <i>in Vitro</i> purging of human bone marrow," <i>Cancer Research</i> , 50:1170-1175, 1990. |
| | C201 | Topp <i>et al.</i> , "MUC-1 specific T-cells are present in multiple myeloma patients at high frequency after allogeneic transplantation but may not mediate the graft versus myeloma effect," <i>Blood</i> , 100: page Abstract No. 5191, 2002. |
| | C202 | Torchilin and Levchenko, "TAT-liposomes: a novel intracellular drug carrier," <i>Curr. Protein Pept. Sci.</i> , 4:133-40, 2003. |

25794698.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)
ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /SM/

| | | | |
|--|--|---|-----------------------------------|
| Form PTO-1449 (modified) | | Atty. Docket No.: DFCI:006US | Serial No.: 10/598,295 |
| List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT <small>(Use several sheets if necessary)</small> | | | |
| U.S. Patent Documents <i>See Page 1-2</i> | | Foreign Patent Documents <i>See Page 2</i> | Other Art <i>See Page 3-19</i> |

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

| Exam. Init. | Ref. Des. | Citation |
|-------------|-----------|---|
| | C203 | Tseng <i>et al.</i> , "Translocation of liposomes into cancer cells by cell-penetrating peptides penetratin and tat: a kinetic and efficacy study," <i>Mol. Pharmacol.</i> , 62:864-72, 2002. |
| | C204 | Urban-Klein <i>et al.</i> , "RNAi-mediated gene-targeting through systemic application of polyethylenimine (PEI)-complexed siRNA <i>in vivo</i> ," <i>Gene Therapy</i> , 12:461-466, 2005. |
| | C205 | van Hof <i>et al.</i> , "Biodistribution of 111Indium-labeled engineered human antibody CTMO1 in ovarian cancer patients: influence of protein dose," <i>Cancer Research</i> , 56:5179-5185, 1996. |
| | C206 | Verhagen <i>et al.</i> , "Identification of DIABLO, a Mammalian Protein that Promotes Apoptosis by Binding to and Antagonizing IAP Proteins," <i>Cell</i> , 102:43-53, 2000. |
| | C207 | Vermeer <i>et al.</i> , "Segregation of receptor and ligand regulates activation of epithelial growth factor receptor," <i>Nature</i> , 422:322-326, 2003. |
| | C208 | Vives <i>et al.</i> , "A truncated HIV-1 Tat protein basic domain rapidly translocates through the plasma membrane and accumulates in the cell nucleus," <i>J. Biol. Chem.</i> , 272:16010-7, 1997. |
| | C209 | Walczak <i>et al.</i> , "TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL," <i>EMBO J.</i> , 16:5386-5397, 1997. |
| | C210 | Walczak <i>et al.</i> , "Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand <i>in vivo</i> ," <i>Nat. Med.</i> , 5:157-163, 1999. |
| | C211 | Walsh <i>et al.</i> , "Heterogeneity of MUC1 expression by human breast carcinoma cell lines <i>in vivo</i> and <i>in vitro</i> ," <i>Breast Cancer Research and Treatment</i> , 58:255-266, 2000. |
| | C212 | Wang and El-Deiry, "TRAIL and apoptosis induction by TNF-family death receptors," <i>Oncogene</i> , 24:8628-8633, 2003. |
| | C213 | Wei <i>et al.</i> , "MUC1 oncoprotein stabilizes and activates estrogen receptor α ," <i>Molecular Cell</i> , 21:295-305, 2006. |
| | C214 | Wender <i>et al.</i> , "The design, synthesis, and evaluation of molecules that enable or enhance cellular uptake: peptoid molecular transporters," <i>Proc. Natl. Acad. Sci., U.S.A.</i> , 97:13003-8, 2000. |
| | C215 | Williams <i>et al.</i> , "Selective inhibition of growth factor-stimulated mitogenesis by a cell-permeable Grb2-binding peptide," <i>J. Biol. Chem.</i> , 272:22349-54, 1997. |

25794698.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)
ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /SM/

| | | | |
|---|--|---|-----------------------------------|
| Form PTO-1449 (modified) | | Atty. Docket No.: DFCL006US | Serial No.: 10/598,295 |
| List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary) | | | |
| U.S. Patent Documents <i>See Page 1-2</i> | | Foreign Patent Documents <i>See Page 2</i> | Other Art <i>See Page 3-19</i> |

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

| Exam. Init. | Ref. Des. | Citation |
|-------------|-----------|--|
| | C216 | Wreschner <i>et al.</i> , "Does a novel form of the breast cancer marker protein MUC1, act as receptor molecule that modulates signal transduction," In: <i>Antigen and Antibody Molecular Engineering in Breast Cancer Diagnosis and Treatment</i> , Ed. Ceriani Plenum Press, New York, pp. 17-26, 1994. |
| | C217 | Xia <i>et al.</i> , "siRNA-mediated gene silencing in vitro and invivo," <i>Nature Biotechnology</i> , 20:1006-1010, 2002. |
| | C218 | Yamamoto <i>et al.</i> , "Interaction of the DF3/MUC1 breast carcinoma-associated antigen and beta-catenin in cell adhesion," <i>J. Biol. Chem.</i> , 272:12492-4, 1997. |
| | C219 | Yang <i>et al.</i> , "Prevention of Apoptosis by Bcl-2: Release of Cytochrome c from Mitochondria Blocked," <i>Science</i> , 275:1129-1132, 1997. |
| | C220 | Zimmerman <i>et al.</i> , "RNAi-mediated gene silencing in non-human primates," <i>Nature</i> , 441:111-114, 2006. |
| | C221 | Zrihan-Licht <i>et al.</i> , "Characterization and molecular cloning of a novel MUC1 protein, devoid of tandem repeats, expressed in human breast cancer tissue," <i>Eur. J. Biochem.</i> , 224:787-795, 1994. |
| | C222 | Zrihan-Licht <i>et al.</i> , "Tyrosine phosphorylation of the MUC1 breast cancer membrane proteins: cytokine receptor-like molecules," <i>FEBS Lett.</i> , 356:130-136, 1994. |

25794698.1

| | | | |
|-----------|----------------|------------------|------------|
| EXAMINER: | /Sean McGarry/ | DATE CONSIDERED: | 06/17/2009 |
|-----------|----------------|------------------|------------|

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609, DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)
ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /SM/